EC Number   |
Inhibitors |
Structure |
|---|
   3.4.22.62 | (3S,6S,10aS)-6-(L-alanylamino)-N-(diphenylmethyl)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide |
- |
   |
| 3.4.22.62 | (3S,6S,8aS)-6-(L-alanylamino)-N-(diphenylmethyl)-5-oxooctahydroindolizine-3-carboxamide |
- |
|
| 3.4.22.62 | (3S,6S,9aS)-6-(L-alanylamino)-N-(diphenylmethyl)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepine-3-carboxamide |
- |
|
| 3.4.22.62 | acetyl-AEVD-CHO |
- |
|
| 3.4.22.62 | acetyl-DEVD-CHO |
- |
|
| 3.4.22.62 | acetyl-DVAD fluoromethyl ketone |
prediction of the tertiary structure of a caspase-9/inhibitor complex |
|
| 3.4.22.62 | acetyl-IETD-CHO |
- |
|
| 3.4.22.62 | acetyl-WEHD-CHO |
- |
|
| 3.4.22.62 | acetyl-YVAD-CHO |
- |
|
| 3.4.22.62 | ATP |
enzyme activity is inhibited in both normoxic and hypoxic groups. The IC50 increases 5fold following hypoxia, suggesting a hypoxia-induced modification of the ATP binding site. 70% inhibition by 1 mM |
|
